Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05466591
Other study ID # NL 66755.091.18
Secondary ID NTR7346NTR734685
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date May 4, 2023

Study information

Verified date July 2022
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with chest pain suspected for non ST-segment elevation acute coronary syndrome (NSTE-ACS) are routinely transferred to the emergency department (ED). A point-of-care (POC) troponin measurement might enable ambulance paramedics to identify low-risk patients in whom ED evaluation is not necessary. The ARTICA trial aims to assess the healthcare cost reduction and safety of a pre-hospital rule-out strategy using a single POC troponin measurement.


Description:

Patients with chest pain suspected of a NSTE-ACS are screened by ambulance paramedics. The HEAR score (HEART score without the Troponin component) is assessed and patients with a HEAR score of ≤3 are included. The patients are randomised to 1) pre-hospital rule-out with POC troponin measurement (intervention group) and 2) direct transfer to the ED (standard care group). Primary outcome is healthcare costs after 30 days.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 866
Est. completion date May 4, 2023
Est. primary completion date June 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Age at least 18 years; male ánd female - All out-of-hospital patients with chest pain or symptoms suggestive of ACS initially visited by an ambulance with an indication for transfer to a hospital to evaluate and rule out ACS - Symptom duration for at least two hours - Modified HEAR(T) score less or equal than 3 - A point of care troponin below the upper reference limit (for patients stratified to pre-hospital management by the general practitioner) - The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion criteria: - Electrocardiographic ST-segment elevation - Patients presenting an obvious non-cardiac cause for the chest complaints who need evaluation at an emergency department, e.g. trauma, pneumothorax, sepsis, etc. - Patients in comatose state, defined as an Glascgow coma scale (GCS) <8 - Patients with known cognitive impairment - Pregnancy or intention to become pregnant during the course of the study - Patients presenting cardiogenic shock, defined as: systolic blood pressure <90 mmHg and heart rate >100 beats per minute and peripheral oxygen saturation <90% (without oxygen administration) - Patients presenting with syncope - Patients presenting with signs of heart failure - Patients presenting with heart rhythm disorders and second or third degree atrioventricular block - Patients with known end-stage renal disease (dialysis and/or glomular filtration rate (GFR) < 30 ml/min) - Patients without a pre-hospital 12-lead ECG performed or available - Patients suspicious of aortic dissection or pulmonary embolism - Patients with confirmed acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting <30 days prior to inclusion - Communication issues with patient/language barrier - Decision of a present general practitioner to evaluate the patient at the emergency department (ED) - Decision of the consultant cardiologist to evaluate patient at the ER irrespective of HEART score - Any significant medical or mental condition, which in the Investigators opinion may interfere with the patients optimal participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Pre-hospital rule-out strategy
Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome

Locations

Country Name City State
Netherlands RadboudUMC Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Costs from a healthcare perspective (all costs related to healthcare consumption in-hospital, all outpatient visits including diagnostic tests and general practitioner consultations) Healthcare costs consist of all costs related to healthcare consumption 30 days
Secondary Safety: all cause death, acute coronary syndrome, unplanned revascularisation Major adverse cardiac events (all cause death, ACS, unplanned revascularisation) 30 days
Secondary Costs from a societal perspective (all health effects and changes in resource use caused by an intervention) Costs from a societal perspective are defined as the sum of the healthcare costs and the costs from productivity losses. 30 days
Secondary Safety (all cause death, acute coronary syndrome, unplanned revascularisation) Major adverse cardiac events (all cause death, ACS, unplanned revascularisation) 6 months
Secondary Safety (all cause death, acute coronary syndrome, unplanned revascularisation) Major adverse cardiac events (all cause death, ACS, unplanned revascularisation) 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study

External Links